The mosquito-borne Zika virus has been around for decades, but there are no approved Zika vaccines available in the USA. However, these are several Zika vaccine candidates in various stages of a clinical study. Vaccine development research is ongoing to investigate the effects of Zika virus infection on pregnancy outcomes, strategies for prevention and control, and effects of infection on other neurological disorders in children and adults.
Zika Vaccine Candidates
Clinical trials involving candidate DNA and purified inactivated virus vaccines showed all were safe and well-tolerated in small studies and all induced neutralizing antibodies, although these studies varied by vaccine candidate and dosing regimen. These results suggest that a Zika vaccine can be developed.
- TAK-426 (PIZV) is a purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate.
- MV-ZIKA-RSP Zika vaccine candidate launches phase 1 clinical trial.
- mRNA-1893 contains an mRNA sequence encoding for the structural proteins of the Zika virus and is designed to cause cells to secrete virus-like particles, mimicking the response of the cell after natural infection.
- ZPIV is a Zika virus vaccine candidate that consists of a purified formalin-inactivated Zika virus.
- INO-A002 is a DNA-encoded monoclonal antibody (dMAb™) technology, candidate.
- VLA1601 is a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum).
- VRC5283 is a Zika Virus DNA Vaccine composed of a single closed-circular DNA plasmid that encodes with wild type precursor transmembrane M and envelope proteins from the H/PF/2013 strain of ZIKV.
Zika Virus Overview
Zika virus is spread mainly through the bite of an infected mosquito. Female mosquitoes can bite several people in a short period of time, meaning that a Zika-carrier has the potential to spread the virus rapidly. Until a Zika preventive vaccine becomes available, pregnant women should delay visiting Zika endemic countries.
Zika virus infection during pregnancy is a cause of microcephaly and other congenital abnormalities in the developing fetus and newborn. Zika infection in pregnancy also results in pregnancy complications such as fetal loss, stillbirth, and preterm birth. Zika virus infection is also a trigger of Guillain-Barré syndrome, neuropathy, and myelitis, particularly in adults and older children.
While Zika virus-associated birth defects have been well-documented, it was unknown if most of the infants who were potentially exposed to Zika (90% to 95%) without developing Zika-associated birth defects had a higher-than-baseline risk of neurodevelopmental abnormalities.
"Understanding the full spectrum of effects associated with congenital Zika virus exposure will help public health respond quickly to future outbreaks, prevent Zika virus infection whenever possible, and provide the most up-to-date clinical guidance for the care of infants and children with congenital Zika virus exposure," researchers concluded.
Zika Vaccine News
Zika health and vaccine news are published by ZikaNews, such as the following articles:
- January 7th, 2020 – A new study suggests the need for long-term neurodevelopmental monitoring for all infants with Zika virus exposure to ascertain the impact of the virus as the infected child ages.
- January 1, 2020 – The Centers for Disease Control and Prevention said that there have not been any local transmissions of the Zika virus in the continental United States, as of December 5, 2019.
- November 29, 2019 – A recent study found about 32 percent of children born to mothers with probable or confirmed Zika virus infection had below average or poor scores when tested at age 18 months.
- November 18, 2019 - The CDC updated its Zika testing guidance.
Zika vaccine content sources include, but are not limited to, the World Health Organization, the US Centers for Disease Control and Prevention, clinicaltrials.gov, and the Precision Vaccinations news network.